Loading
RayzeBio (BMS)
RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.
Overview
RayzeBio, based in San Diego, is the actinium-225 radiopharmaceutical company that Bristol Myers Squibb bought for 4.1 billion dollars, and its RYZ101 is in phase 3. RYZ101 is actinium-225 DOTATATE for somatostatin-receptor-positive neuroendocrine tumours, RYZ801 is an actinium-225 PSMA agent, and the company built in-house actinium-225 manufacturing. OnCo links it to neuroendocrine tumours, to peptide receptor radionuclide therapy and targeted alpha therapy, to the actinium-225 DOTATATE drug record, and to the radiopharmaceutical roadmap from iodine through lutetium to actinium. Whether an alpha emitter can improve on lutetium-based radioligand therapy is the question RYZ101's phase 3 will answer. Actinium-225 DOTATATE has its own page.
Headquarters
San Diego, CA, US
Scorecard
All companies#403of 1245 companies, score 9
- phase 3 +3
- targets +2
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2023-12-26 | RayzeBio (BMS) to Bristol Myers Squibb RYZ101 (actinium-225 DOTATATE) and an actinium-based radiopharmaceutical platform | Acquisition | not disclosed | $4.1bn | source |
Website
Products
1Phase 3Targeted alpha therapy
An alpha-particle version of Lutathera for neuroendocrine tumours that have stopped responding to the beta version.
Connected
9Similar pages
- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 DOTATATE, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyITM Isotope Technologies Munich
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy.
- CompanyOrano Med
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy.
- CompanyTerraPower Isotopes
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- TrialACTION-1
Shares Actinium-225 DOTATATE, Targeted alpha therapy, Neuroendocrine tumours.
- Treatment212Pb-DOTAMTATE
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
- CompanyFusion Pharmaceuticals (AstraZeneca)
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- TrialALPHAMEDIX-02
Shares Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
cancers
fronts
technologies
drugs
Phase 3Targeted alpha therapy
trials
roadmaps
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
rayzebio.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-17 · Jude Gomila · Reverse links for orphaned trials · diff · file · history
Sourced, not expert-reviewed